CorWave

CorWave announced today that chronic in vivo studies of its implantable heart pump have proven “unprecedented” with strong results.

Presenting at the annual meeting for the International Society for Heart and Lung Transplantation (ISHLT), CorWave touted the study as the first ever to demonstrate sensorless synchronization of a pericardial pump with the native heart for over 30 days, according to a news release.

Clichy, France’s implantable left ventricular assist device (LVAD), which uses its breakthrough wave membrane pump technology, is designed to offer a wide range of flow conditions, gentle blood propulsion and to generate physiologic pulsatility in an effort to reduce the adverse events associated with current LVAD technologies.

Study results from the trials in which the CorWave device operated in pulsatile mode by synchronizing with the native heart without the aid of sensors demonstrated more than 97% success in detecting heartb…

CorWave announced today that it raised $40 million from a mix of returning and new investors for its wave membrane heart pump.

Clichy, France-based CorWave received funding — from three new investors joining its returning investors — which is earmarked for its implantable left ventricular assist device (LVAD) which uses its breakthrough wave membrane pump technology, according to a news release.

The funding collected in the round is slated to help the company finalize the development of its initial product, expand its manufacturing infrastructure, complete the regulatory processes required to conduct human implants and start its human clinical trials.

Existing shareholders Bpifrance, Novo Holdings, Seventure, Sofinnova Partners and Ysios Capital all significantly increased their stake in the company as part of the financing, too.

“This $40 million round gives us the means to achieve our ambitions,” CorWave CEO Louis de Lillers said in …